Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer

He, Chao; Bian, Xueyi; Ni, Xiaoqing; Shen, Danhong; Shen, Yanying; Liu, Hua; Shen, Zhiyong; Liu, Qiang

doi:10.3748/wjg.v19.i14.2171

Cited by 84 publications

(74 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…SUV max was significantly lower in the HER2-positive group than in the HER2-negative group. Our data also demonstrated that HER2 expression is more common in well-or moderately differentiated adenocarcinoma than in poorly differentiated adenocarcinoma; this finding is consistent with the findings of previous studies (20)(21)(22). In addition, well-or moderately differentiated adenocarcinoma had significantly lower 18 F-FDG uptake than did poorly differentiated adenocarcinoma, partly explaining why patients with HER2 expression had a low SUV max (excluding signet-ring cell carcinoma from the analysis).…”

Section: Discussionsupporting

confidence: 82%

See 1 more Smart Citation

Relationship Between ¹⁸F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer

Chen

Zhou

et al. 2016

J Nucl Med

View full text Add to dashboard Cite

18 F-FDG PET has been widely used in the management of malignant tumors. In gastric cancer, the status of human epidermal growth factor receptor 2 (HER2) predicts the response to anti-HER2 antibody therapy, and testing of HER2 expression is now routine in the management of gastric cancer patients. However, to date, the relationship between 18 F-FDG uptake and HER2 expression has not, to our knowledge, been investigated. In this study, we aimed to investigate whether HER2 expression is associated with 18 F-FDG uptake and whether 18 F-FDG PET/CT can be used to predict the HER2 status of gastric cancer. Methods: A retrospective analysis was performed on 64 gastric cancer patients who had undergone 18 F-FDG PET/CT before surgical resection. Tumor SUV max was calculated from the level of 18 F-FDG uptake. Results: No significant correlation was found between SUV max and HER2 expression in gastric cancer. However, when signet-ring cell carcinoma was excluded, SUV max was significantly higher in the HER2-negative group than in the HER2-positive group (8.619 ± 5.878 vs. 3.789 ± 2.613, respectively; P 5 0.021). Multivariate analysis indicated that SUV max and tumor differentiation remained significantly associated with HER2 expression (P 5 0.048 and P 5 0.028, respectively). HER2 expression was predicted with an accuracy of 64.4% when an SUV max cutoff of 6.2 was used. Conclusion: 18 F-FDG uptake by gastric cancer is associated with HER2 expression. 18 F-FDG PET/CT may be useful for predicting the HER2 status of gastric cancer and for determining the therapeutic strategy.

show abstract

Section: Discussionsupporting

confidence: 82%

“…The role of HER2 as a prognostic factor in gastric carcinoma has been controversial. Some studies failed to find an association with prognosis (21,25), whereas others found a direct correlation between HER2 expression or amplification and poor survival (22,26). In our study, most cases were from recent years and the sample size was small.…”

Section: Discussionmentioning

confidence: 76%

Relationship Between ¹⁸F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer

Chen

Zhou

et al. 2016

J Nucl Med

View full text Add to dashboard Cite

show abstract

“…Regarding anatomical location similar finding have been reported, with no difference between proximal and distal tumor, as we have found in our study (3,9,10,14,18,21) . Most studies conducted in Asia have also reported reactivity rates of 11.7% to 15.74%, similar to our findings, as well as the predominance of HER2 expression in the intestinal subtype (11,16,17,22) . Only one study from Japan showed different prevalence of HER2 expression regarding to anatomical distribution.…”

Section: Discussionsupporting

confidence: 80%

“…Hoffmann's criteria is based on the percentage of cells with membrane-like staining (11,12) . Grades are classified as follows: grade 0: no reaction or <10% reactivity in tumor cells; grade 1+: weak reactivity >10% of the tumor cells; with reactivity only in part of the membrane; grade 2+: moderate reactivity in >10% of the cells, with staining across the lateral and basolateral membrane: grade 3+: strong reactivity with intense staining of the lateral and basolateral membrane in >10% of the cells.…”

Section: Methodsmentioning

confidence: 99%

Immunohistochemical Expression of Her2 in Adenocarcinoma of the Stomach

Carli

Rocha

Antunes

et al. 2015

Arq. Gastroenterol.

View full text Add to dashboard Cite

-Background -Worldwide, gastric cancer is the fourth cancer in incidence and the second most common cause of cancer death. Gastric cancer is asymptomatic in the early stages and very often diagnosed at advanced stages, determining a dismal prognosis. Expression of the HER2 gene has been identified in about 20% of gastric cancer cases, and its hyper-expression is associated with poor prognosis. Objective -To investigate HER2 immunohistochemical expression in gastric adenocarcinoma and its relationship to the histological type and anatomic location. Methods -A cross-sectional retrospective study analyzed the immunohistochemical expression of HER2 in a sample of 48 specimens of gastric cancer. Immunohistochemical analysis were performed using avidin-biotin-peroxidase method with C-erb B2 (clone EP1045Y), as a primary antibody (Biocare Medical, USA). Standardized gastric adenocarcinoma's HER2 expression criteria has been used in the analysis of samples. Results -There were seven cases with reactivity for HER2. Five were of intestinal-type while two cases were of mixed-type in which the expression occurred in the intestinal component. It was identified a significant association of HER2 expression in the intestinal subtype of gastric adenocarcinoma (P=0.003).Regarding the anatomical site, HER2 was positive in only one (16.6%) of the six proximal cases and six (14.28%) of the 42 distal cases (P=0.88). Conclusion -HER2 immunoexpression was identified in 14.6% of the samples, and the expression was significantly associated to Lauren's intestinal subtype. HEADINGS -Immunohistochemistry. Stomach neoplasms. erbB-2 genes.

show abstract

“…Regarding HER2 and EGFR, our results were similar to those of previous reports with regard to the clinicopathological features and prognosis of each RTK-overexpressing tumor [26,[36][37][38][39][40][41]. However, contrary to previous reports, MET-overexpressing GACs tended to be associated with a rather favorable outcome in our study [25,42,43].…”

Section: Discussioncontrasting

confidence: 57%

Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma

et al. 2014

View full text Add to dashboard Cite

Background Some tyrosine kinase receptors (RTKs) play critical roles in gastric cancer progression. Not only trastuzumab, but also several other agents targeting RTKs are being investigated for gastric cancer therapy. However, the simultaneous expression of multiple RTKs, which may interfere with the effectiveness of therapeutic agents, has not been evaluated in a large cohort with gastric adenocarcinoma (GAC). Methods We performed a tissue microarray analysis in 950 patients with GAC who underwent a gastrectomy without preoperative chemotherapy. The protein expressions of HER2, EGFR, MET and FGFR2 were evaluated using immunohistochemistry, and the gene amplifications of HER2, EGFR and MET were examined using dual-color in situ hybridization.Results The frequency of overexpression was 11.8 % for HER2, 23.5 % for EGFR, 24.9 % for MET and 31.1 % for FGFR2. Whereas strong staining for each of the RTKs was heterogeneous, tumors with homogeneously strong staining areas often exhibited gene amplification. Strong EGFR expression was significantly associated with a poor outcome, but no prognostic correlations were observed in other RTKs. The overexpression of single and multiple RTKs was observed in 40.4 and 22.7 % of the cases, respectively. HER2, EGFR, MET and FGFR2 predominance was observed in 10.1, 13.9, 16.1 and 22.9 % of the GACs, respectively. Conclusions Approximately two-thirds of patients with GAC exhibited the expression of at least one RTK and would be candidates for targeted therapies. Moreover, one-third of at least one RTK overexspressing cases showed multiple RTKs expression. Our results may be useful for selecting the most suitable patients for each targeted therapy.

show abstract

Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer

Abstract: Patients with intestinal type gastric cancer (GC), well-differentiated GC and poorly-differentiated GC without lymph node metastasis, may all represent suitable candidates for targeted therapy using Herceptin.

Cited by 84 publications

References 36 publications

Relationship Between ¹⁸F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer

Relationship Between ¹⁸F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer

Immunohistochemical Expression of Her2 in Adenocarcinoma of the Stomach

Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma

Contact Info

Product

Resources

About

Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer

Abstract: Patients with intestinal type gastric cancer (GC), well-differentiated GC and poorly-differentiated GC without lymph node metastasis, may all represent suitable candidates for targeted therapy using Herceptin.

Cited by 84 publications

References 36 publications

Relationship Between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer

Relationship Between 18F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer

Immunohistochemical Expression of Her2 in Adenocarcinoma of the Stomach

Expression profiles of HER2, EGFR, MET and FGFR2 in a large cohort of patients with gastric adenocarcinoma

Contact Info

Product

Resources

About

Relationship Between ¹⁸F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer

Relationship Between ¹⁸F-FDG PET/CT Findings and HER2 Expression in Gastric Cancer